MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rmed.2023.107374

Медицинская библиотека · Respiratory medicine · 2023

Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.

Miller Chad E, Franco Veronica, Smith Jimmy S, Balasubramanian Vijay, Kingrey John, Zolty Ronald, Melendres-Groves Lana, Huston Jessica, Elwing Jean M, Ravichandran Ashwin, Cella Dana, Shen Eric, Seaman Scott, Thrasher Claire M, Broderick Meredith, Oudiz Ronald J

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАКлиническое исследование IV фазыПеревод в очереди

Аннотация

RATIONALE: Oral treprostinil slows disease progression and improves exercise capacity in pulmonary arterial hypertension; however, titration can be prolonged. Published data suggests prostacyclin-naïve patients achieve total daily oral treprostinil doses of about 6 mg by Week 16, while those on prior parenteral treprostinil reach higher doses at the same timepoint.

OBJECTIVES

EXPEDITE (NCT03497689), a single-arm, multicenter study, assessed the efficacy of rapid parenteral treprostinil induction to quickly reach higher doses of oral treprostinil for the treatment of pulmonary arterial hypertension.

METHODS

Parenteral treprostinil was titrated for 2-8 weeks, followed by cross-titration of oral treprostinil. The primary endpoint was percentage of patients reaching ≥12 mg daily of oral treprostinil at Week 16. Secondary endpoints included clinical changes from baseline to Week 16.

RESULTS

Twenty-nine prostacyclin-naïve patients were included in efficacy analyses. At Week 16, the mean daily oral treprostinil dose was 16.4 mg; 79% of patients met the primary endpoint. From baseline to Week 16, median REVEAL Lite 2 score improved (decreased) from 6 to 3.5 (p = 0.0006). Statistically significant improvements were also seen in World Health Organization Functional Class, N-terminal-pro brain natriuretic peptide levels, 6-minute walk distance, right atrial area, Borg Dyspnea Score, and emPHasis-10 score. Favorable trends were seen in risk stratification, echocardiography parameters, disease symptoms, and treatment satisfaction.

CONCLUSION

Short-course parenteral treprostinil induction resulted in oral treprostinil doses over twice those reported in de novo initiations and may be a useful approach to quickly achieve the therapeutic benefits of oral treprostinil.

Для цитирования: Miller Chad E, Franco Veronica, Smith Jimmy S, Balasubramanian Vijay, Kingrey John, Zolty Ronald, Melendres-Groves Lana, Huston Jessica, Elwing Jean M, Ravichandran Ashwin, Cella Dana, Shen Eric, Seaman Scott, Thrasher Claire M, Broderick Meredith, Oudiz Ronald J. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.. Respiratory medicine. 2023. DOI: 10.1016/j.rmed.2023.107374.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.